Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.
News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...
USPTO mass resignation concerns; INPI president interview; WTR summit speaker line-up; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...
Developers summoned; Xerotech on the brink; Glencore eyes Pallas Green sale; CRH invests in 3D; Mounjaro arrives; and O’Hara ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback